Bikash Agarwal, MD
Internal Medicine · Michigan City, INNPI 1093700825
Payments from drug & device makers
Across 41 payments — averaging $52.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$413
- Inari Medical, Inc.$336
- Amgen$250
- Novo Nordisk$194
- Vifor Pharma, Inc.$148
- Lilly USA, LLC$125
- plus $692 from 15 others
What the payments were for
- Food & beverage$2,157100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 3 | $413 |
| Inari Medical, Inc. | 2 | $336 |
| Amgen(2 entities) | 2 | $250 |
| Novo Nordisk | 5 | $194 |
| Vifor Pharma, Inc. | 2 | $148 |
| Lilly USA, LLC | 1 | $125 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| ANI Pharmaceuticals, Inc. | 1 | $125 |
| AstraZeneca | 4 | $90 |
| Edwards Lifesciences | 1 | $67 |
| AbbVie | 3 | $61 |
| Pfizer | 3 | $42 |
| Johnson & Johnson | 3 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| GSK | 2 | $28 |
| Dexcom, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $11 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$459
- WATCHMAN Access System$267
- KRYSTEXXA$250
- CT THROMBECTOMY SYSTEM KIT$214
- WATCHMAN FLX$146
- NEXLIZET$125
- NEXLETOL$125
- Veltassa$125
- Ozempic$125
- PURIFIED CORTROPHIN GEL$125
- JARDIANCE$125
How this compares
$2,158 in reported general payments places this provider in the 85th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 389 | $143,223 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 125 | $116,469 |
| JardianceEmpagliflozin | 175 | $104,960 |
| OzempicSemaglutide | 30 | $36,344 |
| XareltoRivaroxaban | 48 | $33,937 |
| XifaxanRifaximin | 58 | $33,016 |
| JanuviaSitagliptin Phosphate | 38 | $32,922 |
| MyrbetriqMirabegron | 104 | $21,315 |
| EntrestoSacubitril/Valsartan | 77 | $20,620 |
| Breo ElliptaFluticasone/Vilanterol | 47 | $20,137 |
| MounjaroTirzepatide | 15 | $17,966 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $16,750 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $15,731 |
| Atorvastatin Calcium | 1,030 | $8,786 |
| Memantine Hcl | 243 | $7,043 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $28 | $153,355203 claims |
| PfizerEliquis, Abrysvo | $42 | $146,679400 claims |
| MerckJanuvia, Verquvo | $16 | $38,25854 claims |
| Novo NordiskOzempic | $194 | $36,34430 claims |
| Johnson & JohnsonXarelto | $41 | $33,93748 claims |
| Lilly USA, LLCMounjaro | $125 | $17,96615 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $1 | $6,43041 claims |
| Sanofi-aventis U.S. LLCLantus | $37 | $5,05134 claims |
| AstraZenecaBrilinta | $90 | $4,96512 claims |
| AbbVieSynthroid | $61 | $2,45438 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Michigan City
- Minesh PatelMichigan City$275K
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.